Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2004-11-02
2010-10-12
Padmanabhan, Sreeni (Department: 1627)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S366000, C514S250000, C514S043000, C514S220000, C514S420000, C600S001000
Reexamination Certificate
active
07812034
ABSTRACT:
Liposarcomas are treated using HIV protease inhibitors, particularly nelfinavir. The protease inhibitors may be used alone or in combination with traditional cancer treatments, such as chemotherapy, radiotherapy, or surgery.
REFERENCES:
patent: 2002/0150534 (2002-10-01), Yu et al.
patent: 2006/0088545 (2006-04-01), Ensoli
Bolen, “Liposarcomas a Histogenic Approach to the Classification of Adipose Tissue Neoplasms”, American Journal of Sugical Pathology, 1984, 8, pp. 3-17.
Brennan, M.F., et al. Soft tissue sarcoma. In: DeVita VT Jr., Hellman S, Rosenberg SA, eds.Cancer: Principles&Practice of Oncology. 6thed. Philadelphia, PA: Lippincott-Raven Publishers, (2001).
Patel, S.R., et al. Myxoid liposarcoma: experience with chemotherapy.Cancer74: 1265-1269 (1994).
Antman K, Crowley J, Balcerzak SP, Rivkin SE, Weiss GR, Elias A, Natale RB, Cooper RM, Barlogie B, Trump DL, Doroshow JH, Aisner J, Pugh RP, Weiss RB, Cooper BA, Clamond GH, and Baker LH. An Intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas.J Clin Oncol11: 1276-1285, 1993.
Atherton, D. J.; Pitcher, D. W.; Wells, R. S.; MacDonald, D. M.: A syndrome of various cutaneous pigmented lesions, myxoid neurofibromata and atrial myxoma: the NAME syndrome.Brit. J. Derm. 103: 421-429, 1980.
Bernstein E, Caudy AA, Hammond SM, and Hannon GJ. Role for a bidentate ribonuclease in the initiation step of RNA interference.Nature409: 363-366, 2001.
Borden EC, Baker LH, Bell RS, Bramwell V, Demetri GD, Eisenberg BL, Fletcher CDM, Fletcher JA, Ladanyi M, Meltzer P, O'Sullivan B, Parkinson DR, Pisters PWT, Saxman S, Singer S, Sundaram M, van Oosterom AT, Verweij J, Waalen J, Weiss SW, and Brennan MF. Soft tissue sarcomas of adults: state of the translational science.Clin Cancer Res9: 1941-1956, 2003.
Caron M, Auclair M, Vigouroux C, Glorian M, Forest C, and Capeau J. The HIV protease inhibitor indinavir impairs sterol regulatory element-biding protein-1 intranuclear localization, inhibits preadipocyte differentiation, and induces insulin resistance.Diabetes50: 1378, 2001.
Carr A, Samaras K, Chisholm DJ, and Cooper DA. Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance.Lancet351: 1881-1883, 1998.
Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chisholm DJ, and Cooper DA. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidemia, and diabetes mellitus.Lancet353: 2093-2099, 1999.
Chow WA, and Doroshow JH. The Ewing's family of tumors (EFT) express the KIT and PDGFR-αtyrosine kinase receptors.Proc Amer Assoc Cancer Res43: 1668, 2002.
Chow WA, Wilczynski SP, and Doroshow JH. Receptor tyrosine kinase inhibition in Ewing's family of tumors.Proc Amer Assoc Cancer Res. 44: 4700, 2003.
Coindre J-M, Terrier P, Guillou L, Le Doussal V, Collin F, Ranchère D, Sastre X, Vilain M-O, Bonichon F, and N'Guyen Bui B. Predictive value of grade for metastasis development in the main histologic types of adult soft tissue sarcomas: a study of 1240 patients from the French Federation of Cancer Centers Sarcoma Group.Cancer91: 1914-1926, 2001.
Demetri GD, Fletcher CDM, Mueller E, Sarraf P, Naujoks R, Campbell N, Spiegelman BM, and Singer S. Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-γ ligand troglitazone in patients with liposarcoma.Proc Natl Acad Sci USA96: 3951-3956, 1999.
Dowell P, Flexner C, Kwiterovich PO, and Lane MD. Suppression of preadipocyte differentiation and promotion of adipocyte death by HIV protease inhibitors.J Biol Chem52: 41325-41332, 2000.
Figgitt DP, and Plosker GL. Saquinavir soft-gel capsule: an updated review of its use in the management of HIV infection.Drugs60: 481-516, 2000.
Flexner C. HIV-protease inhibitors.N. Engl J Med338: 1281-1292, 1998.
Freireich EJ, Gehan EA, Rall DP, Schmidt LH, and Skipper HE. Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man.Cancer Chemo Reports50: 219-244, 1966.
Gossen M, and Bujard H. Tight control of gene expression in mammalian cells by tetracycline-responsive promoters.Proc. Natl. Acad. Sci. USA. 89: 5547-5551, 1992.
Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, and Thun MJ. Cancer statistics, 2003.CA Cancer J Clin53: 5-26, 2003.
Kim JB, and Spiegelman BM. ADD1/SREBP1 promotes adipocyte differentiation and gene expression linked to fatty acid metabolism.Genes & Dev10: 1096-1107, 1996.
Kim JB, Wright HM, Wright M, and Spiegelman BM. ADD1/SREBP1 activates PPARγ through the production of endogenous ligand.Proc. Natl. Acad. Sci. USA. 95: 4333-4337, 1998.
Koeffler HP. Peroxisome proliferator-activated receptor β and cancers.Clin Cancer Res9: 1-9, 2003.
Lairmore, TC, Wells, SA, Jr., Moley, JF, Brennan MF, Cancer of the Endocrine System. In: DeVita VT Jr., Hellman S, Rosenberg SA, eds. Cancer: Principles & Practice of Oncology. 6thed. Philadelphia, PA: Lippincott-Raven Publishers: Chapter 38, pp. 1727-1891, 2001.
Le Grice SFJ, Mills J, and Mous J. Active site mutagenesis of the AIDS virus protease and its alleviation by trans complementation.EMBO J7: 2547-2553, 1988.
McCune JM, Namikawa R, Kaneshima H, Shultz LD, Lieberman M, and Weissman IL. The SCID-hu mouse: murine model for the analysis of human hematolymphoid differentiation and function.Science241: 1632-1639, 1988.
Mendelian Inheritance in Man(OMIN), http://www.ncbi.nlm.nih.gov/, OMIN reference No. 151900. no date available.
Mendelian Inheritance in Man(OMIN), http://www.ncbi.nlm.nih.gov/, OMIN reference No. 160980. no date available.
Palella FJ, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, Aschman DJ, Holmberg SD, and the HIV Outpatient Study Investigators. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection.N Engl J Med338: 853-860, 1998.
Riddle TM, Kuhel DG, Woollett LA, Fichtenbaum CJ, and Hui DY. HIV protease inhibitor induces fatty acid and sterol biosynthesis in liver and adipose tissues due to accumulation of activated sterol regulatory element-binding proteins in the nucleus.J Biol Chem276: 37514-37519, 2001.
Shetty BV, Kosa MB, Khalil DA, and Webber S. Preclinical pharmacokinetics and distribution to tissue of AG1343, an inhibitor of human immunodeficiency virus type I protease.Antimicrob Agents Chemo40: 110-114, 1996.
Shih, C-C, Hu J, Arber D, LeBon T, and Forman SJ. Transplantation and growth characteristics of human fetal lymph node in immunodeficient mice.Exp Hematol28: 1046-1053, 2000.
Shih, CC, Hu MCT, Hu J, Medeiros J, and Forman SJ. Long-term Ex vivo maintenance and expansion of transplantable human hematopoietic stem cells.Blood94: 1623-1636, 1999.
Shih, CC, Weng Y, Mamelak A, LeBon T, Hu MCT, and Forman SJ. Identification of a candidate human neurohematopoietic stem-cell population.Blood98: 2412-2422, 2001.
Sreekantaiah C, Ladanyi M, Rodriguez E, and Chaganti RS. Chromosomal aberrations in soft tissue tumors. Relevance to diagnosis, classification, and molecular mechanisms.Am J Pathol144: 1121-1134, 1994.
Tallman MS, Andersen JW, Schiffer CA, Appelbaum FR Feusner JH, Ogden A, Shepherd L, Willman C, Bloomfield CD, Rowe JM, and Wiernik PH. All-trans-retinoic acid in acute promyelocytic leukemia.N Engl J Med337: 1021-1028, 1997.
Tontonoz P, Hu, E, and Spiegelman BM. Stimulation of adipogenesis in fibroblasts by PPARγ2, a lipid-activated transcription factor.Cell79: 1147-1156, 1994.
Tontonoz P, Singer S, Forman BM, Sarraf P, Fletcher JA, Fletcher CDM, Brun RP, Mueller E, Altiok S, Oppenheim H, Evans RM, and Spiegelman BM. Terminal differentiation of human liposarcoma cells induced by ligands for peroxisome proliferator-activated receptor γ and the retinoid X receptor.Proc. Natl. Acad. Sci. USA. 94: 237-241, 1997.
Warrell RP, Frankel SR, Miller WH, Scheinberg DA, Itri LM, Hittelman WN, Vyas R, Andreeff M, Tafuri A, Jakubowski A, Gabrilove J, Gordon MS, and Dmitrovsky E. Differentiation therapy of acute p
Chow Warren
Shih Chu-Chih
City of Hope
Javanmard Sahar
Padmanabhan Sreeni
Perkins Coie LLP
Sliger Lauren
LandOfFree
Method of using protease inhibitors for the treatment of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of using protease inhibitors for the treatment of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of using protease inhibitors for the treatment of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4213027